It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2018
  5. Otsuka Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti® Tablets for Schizophrenia

January 19, 2018

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

Otsuka Receives Approval in Japan for the Manufacture and Sale
of New Antipsychotic Drug Rexulti® Tablets for Schizophrenia

Otsuka Pharmaceutical Co., Ltd. announces that regulatory approval was received on January 19 for the manufacture and sale of Rexulti Tablets® (generic name is brexpiprazole) in 1mg and 2 mg dosage sizes.

Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases